Evidence of off‐label inhalation therapy on pediatric asthma practice in Japan
Pediatrics International · 2023
DOI: 10.1111/ped.15595 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pediatrics International, 2023. Verfasst von Kenji Oishi und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics and Adolescent Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan. Hauptthemen laut MEDLINE: Asthma, Central Nervous System Stimulants, Anti-Asthmatic Agents. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: JSPS KAKENHI.
Abstract (Originalsprache)
Background
In Japan, many asthma inhalers do not have formal approval for use in the pediatric population because of the lack of domestic data. In real‐world settings, however, numerous off‐label medications are prescribed. Currently, the nature of off‐label prescriptions of asthma inhalers on pediatric patients in Japan remains unclear.
Methods
Using public open‐source national medical claims data, we investigated the real‐world descriptive epidemiology of off‐label prescriptions for asthma inhalers for pediatric patients. We obtained the number of off‐label prescriptions of formulations for patients aged 0–14 years from anonymously summarized prescription data for a 7‐year period starting from April 2014. The actual prescription numbers and their chronology over time were then analyzed.
Results
In 2019, 143,439 asthma inhalers were used off label in children and adolescents. Overall, 96.1% were inhaled corticosteroids (ICSs) or long‐acting beta stimulants (LABAs), and 3.9% were high‐dose ICS. Of ICSs and LABAs, 18.8% were off‐label prescriptions. The total number of off‐label ICS/LABA prescriptions and their percentage relative to the overall formulations gradually decreased but a notable disparity was observed among inhaler types.
Conclusions
There was a surprisingly large number of off‐label prescriptions of asthma inhalers in the pediatric population in Japan. The proper use of ICSs/LABAs and expansion of insurance coverage should be advocated to reduce off‐label use.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics and Adolescent Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan.
- Department of Pediatrics, Juntendo University Faculty of Medicine, Tokyo, Japan.
- Social Insurance Committee, Japan Pediatric Society, Tokyo, Japan.
- Department of Pediatrics, Tokyo Medical and Dental University, Tokyo, Japan.
- Department of Emergency Medicine, Maebashi Red Cross Hospital, Gunma, Japan.
- Department of Pediatrics, Saiseikai Kawaguchi Hospital, Saitama, Japan.
ORCID-Profile: Eisuke Inage, Susumu Yamazaki, Yosuke Baba, Takahiro Kudo, Toshiaki Shimizu
Förderung
- JSPS KAKENHI
Zitieren
APA
Oishi, K., Inage, E., Kojima, M., Yamada, H., Tanaka, Y., Yoneyama, T., Yamazaki, S., Honjo, A., Baba, Y., Kudo, T., Ohtsuka, Y., Endo, A., Nakabayashi, Y., Oyama, S., & Shimizu, T. (2023). Evidence of off‐label inhalation therapy on pediatric asthma practice in Japan. Pediatrics International. https://doi.org/10.1111/ped.15595
Vancouver
Oishi K, Inage E, Kojima M, Yamada H, Tanaka Y, Yoneyama T, et al. Evidence of off‐label inhalation therapy on pediatric asthma practice in Japan. Pediatrics International. 2023. doi:10.1111/ped.15595
BibTeX
@article{Oishi2023,
author = {Oishi, Kenji and Inage, Eisuke and Kojima, Mayuki and Yamada, Hiromichi and Tanaka, Yuko and Yoneyama, Toshiyuki and Yamazaki, Susumu and Honjo, Asuka and Baba, Yosuke and Kudo, Takahiro and Ohtsuka, Yoshikazu and Endo, Akifumi and Nakabayashi, Yosuke and Oyama, Shoichi and Shimizu, Toshiaki},
title = {Evidence of off‐label inhalation therapy on pediatric asthma practice in Japan},
journal = {Pediatrics International},
year = {2023},
doi = {10.1111/ped.15595}
}
EUVIMED